EP1678111A1 - Process for the preparation of alpha- and beta-cryptoxanthin - Google Patents
Process for the preparation of alpha- and beta-cryptoxanthinInfo
- Publication number
- EP1678111A1 EP1678111A1 EP04796640A EP04796640A EP1678111A1 EP 1678111 A1 EP1678111 A1 EP 1678111A1 EP 04796640 A EP04796640 A EP 04796640A EP 04796640 A EP04796640 A EP 04796640A EP 1678111 A1 EP1678111 A1 EP 1678111A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lutein
- cryptoxanthin
- anhydroluteins
- mixture
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 title claims abstract description 138
- 235000002360 beta-cryptoxanthin Nutrition 0.000 title claims abstract description 85
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 title claims abstract description 74
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 title claims abstract description 74
- 239000011774 beta-cryptoxanthin Substances 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 59
- NBZANZVJRKXVBH-DJPRRHJBSA-N (3R,6'R)-beta,epsilon-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=CCCC1(C)C NBZANZVJRKXVBH-DJPRRHJBSA-N 0.000 title claims abstract description 51
- NBZANZVJRKXVBH-GYDPHNCVSA-N alpha-Cryptoxanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]2C(C)=CCCC2(C)C)\C)/C)\C)/C)=C(C)C1 NBZANZVJRKXVBH-GYDPHNCVSA-N 0.000 title claims abstract description 51
- 235000005861 alpha-cryptoxanthin Nutrition 0.000 title claims abstract description 51
- 230000008569 process Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title description 7
- BMQNSHDVIYZULR-WZLJTJAWSA-N anhydrolutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C=CCC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C BMQNSHDVIYZULR-WZLJTJAWSA-N 0.000 claims abstract description 158
- 239000000203 mixture Substances 0.000 claims abstract description 133
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 119
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 117
- 239000001656 lutein Substances 0.000 claims abstract description 106
- 235000012680 lutein Nutrition 0.000 claims abstract description 106
- 229960005375 lutein Drugs 0.000 claims abstract description 106
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 105
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 105
- 239000001257 hydrogen Substances 0.000 claims abstract description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940107604 lutein esters Drugs 0.000 claims abstract description 25
- 150000002658 luteins Chemical class 0.000 claims abstract description 25
- 230000003197 catalytic effect Effects 0.000 claims abstract description 20
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 claims abstract description 12
- 230000007704 transition Effects 0.000 claims abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 108
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 46
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 46
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 39
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 38
- 239000003054 catalyst Substances 0.000 claims description 38
- BMQNSHDVIYZULR-FKKUPVFPSA-N (1r)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexa-1,3-dien-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol Chemical compound CC=1C=CCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C BMQNSHDVIYZULR-FKKUPVFPSA-N 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 33
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical class C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 claims description 31
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 claims description 27
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 25
- -1 Iridium (I) hexafluorophosphate Chemical compound 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 20
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 238000009905 homogeneous catalytic hydrogenation reaction Methods 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 12
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 12
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 12
- 239000011995 wilkinson's catalyst Substances 0.000 claims description 12
- 239000010948 rhodium Substances 0.000 claims description 11
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 10
- 235000010930 zeaxanthin Nutrition 0.000 claims description 10
- 239000001775 zeaxanthin Substances 0.000 claims description 10
- 229940043269 zeaxanthin Drugs 0.000 claims description 10
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 9
- 239000004212 Cryptoxanthin Substances 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 7
- 229910052723 transition metal Inorganic materials 0.000 claims description 7
- 150000003624 transition metals Chemical class 0.000 claims description 7
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 229940035429 isobutyl alcohol Drugs 0.000 claims description 3
- UJNZOIKQAUQOCN-UHFFFAOYSA-N methyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C)C1=CC=CC=C1 UJNZOIKQAUQOCN-UHFFFAOYSA-N 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000000287 crude extract Substances 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 240000000785 Tagetes erecta Species 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 85
- 235000021466 carotenoid Nutrition 0.000 abstract description 66
- 150000001747 carotenoids Chemical class 0.000 abstract description 66
- 238000005984 hydrogenation reaction Methods 0.000 abstract description 27
- 238000006297 dehydration reaction Methods 0.000 abstract description 8
- 230000018044 dehydration Effects 0.000 abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 abstract description 4
- 150000004291 polyenes Polymers 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 53
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 49
- 238000004128 high performance liquid chromatography Methods 0.000 description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 43
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 34
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 241000736851 Tagetes Species 0.000 description 25
- 239000013078 crystal Substances 0.000 description 24
- 239000008601 oleoresin Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 23
- 238000001914 filtration Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 229910052697 platinum Inorganic materials 0.000 description 18
- 239000007858 starting material Substances 0.000 description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 238000005809 transesterification reaction Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- UIUSQYGQZRBKCC-NHWXEJKLSA-N (3R,6'R)-3-hydroxy-3',4'-didehydro-beta,gamma-carotene Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(=C)C=CCC1(C)C UIUSQYGQZRBKCC-NHWXEJKLSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- UIUSQYGQZRBKCC-ITUXNECMSA-N anhydrolutein I Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=C)C=CCC2(C)C UIUSQYGQZRBKCC-ITUXNECMSA-N 0.000 description 10
- 229940105132 myristate Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002815 homogeneous catalyst Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 238000002798 spectrophotometry method Methods 0.000 description 8
- HBHHQQIZEXNSHZ-NHWXEJKLSA-N (1r)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-3,7,12,16-tetramethyl-18-[(1s)-2,6,6-trimethylcyclohexa-2,4-dien-1-yl]octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=CC=CC1(C)C HBHHQQIZEXNSHZ-NHWXEJKLSA-N 0.000 description 7
- MLNBLHZHPFTDGG-UHFFFAOYSA-N Lutein-3-palmitate Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)(C)CC(O)C=C1C MLNBLHZHPFTDGG-UHFFFAOYSA-N 0.000 description 7
- HBHHQQIZEXNSHZ-ITUXNECMSA-N anhydrolutein II Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC=CC2(C)C)C HBHHQQIZEXNSHZ-ITUXNECMSA-N 0.000 description 7
- 230000008033 biological extinction Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 238000007127 saponification reaction Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000002638 heterogeneous catalyst Substances 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229910052703 rhodium Inorganic materials 0.000 description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YHGJHDJZIOYZIR-UHFFFAOYSA-N all-trans-lutein dipalmitate Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)(C)CC(OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-UHFFFAOYSA-N 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- XACHQDDXHDTRLX-HZXCUAKRSA-N zeaxanthin dipalmitate Chemical compound CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-HZXCUAKRSA-N 0.000 description 2
- 150000003749 zeaxanthins Chemical class 0.000 description 2
- MUHONFFTSOCMDH-JXNOXZOESA-N (1z,5z)-cycloocta-1,5-diene;iridium;methyl(diphenyl)phosphane;hexafluorophosphate Chemical compound [Ir].F[P-](F)(F)(F)(F)F.C\1C\C=C/CC\C=C/1.C=1C=CC=CC=1P(C)C1=CC=CC=C1.C=1C=CC=CC=1P(C)C1=CC=CC=C1 MUHONFFTSOCMDH-JXNOXZOESA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000012308 Tagetes Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000005471 carotenols Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002943 palmitic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 150000003785 γ-tocopherols Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/10—The polymethine chain containing an even number of >CH- groups
Definitions
- the invention is in the field of organic chemistry.
- the invention relates to a process that converts a mixture of dehydration products of (3R,3 'R,6 'R)-lutein, hereto after referred to as anhydroluteins, to a mixture of (3R)- ⁇ -cryptoxanthin and (3R,6'R)- -cryptoxanthin by catalytic hydrogenation with a variety of heterogeneous and homogeneous catalysts under mild conditions at atmospheric pressure.
- Two alternative processes have also been developed that can convert unesterii ⁇ ed lutein to anhydroluteins.
- the invention also relates to a process that converts other lutein sources to anhydroluteins.
- CAD coronary artery disease
- CHF congestive heart failure
- CHD coronary heart disease
- angina pectoris angina pectoris
- myocardial infarction onset has all shown to have lower ⁇ -crytpoxanthin levels with respect to healthy age-matched subjects
- CAD coronary artery disease
- CHF congestive heart failure
- CHD coronary heart disease
- angina pectoris angina pectoris
- myocardial infarction onset have all shown to have lower ⁇ -crytpoxanthin levels with respect to healthy age-matched subjects
- AP oxidant stress in angina pectoris
- anhydroluteins I and II are partially isomerized to anhydrolutein III within 7-20 h depending on the nature of the alcohol.
- the resulting product, rich in anhydrolutein III is allowed to react with about 1.3 equivalent of a hydride donor and about 3.5-4 equivalent of a strong organic acid in a chlorinated solvent at ambient temperature for about 1-5 hours to give a mixture o ⁇ E/Z- (3R)- ⁇ -cryptoxanthin, £/Z-(3R,6'R)- -cryptoxanthin, and minor quantities of unreacted anhydroluteins I and II, as well as recovered J E/Z-(3R,3'R)-zeaxanthin.
- the present invention provides an alternative route to the second step of PCT US03/23422 for making (3R)- ⁇ -cryptoxanthin and (3R,6'R)- ⁇ -cryptoxanthin from anhydroluteins and eliminates the use of chlorinated solvents and reagents such as trifluoroacetic acid, and borane-amine complex. This is accomplished by heterogeneous or homogeneous catalytic hydrogenation of anhydroluteins according to the scheme illustrated in Fig 1.
- the present invention improves the first step of transformation of (3R,3'R,6'R)-lutein to anhydroluteins to reduce the amounts of solvents used as well as increasing the purity and stability of the products.
- the present invention will demonstrate that under carefully controlled conditions, hetereogeous and homogeneous catalytic hydrogenation of anhydroluteins with a wide range of catalysts in various solvents can yield a mixture of (3R)- ⁇ -cryptoxanthin and (3R,6'R)- ⁇ -cryptoxanthin in moderate to excellent selectivity and yields. Therefore, in an alternative embodiment, the present invention converts anhydroluteins rich in anhydrolutein III to a mixture of (3R)- ⁇ -cryptoxanthin and (3R,6'R)- ⁇ - cryptoxanthin by heterogeneous catalytic hydrogenation employing transition elements group VIII such as platinum, palladium, or rhodium supported on carbon or alumina at temperatures ranging from
- the homogeneous catalysts may be transition metal complexes such as palladium acetylacetonate, tris(triphenylphosphine)rhodium (I) chloride [Rh(Ph3P) 3 Cl] (Wilkinson's catalyst), (tricyclohexylphosphine)(l,5-cyclooctadiene)pyridine Iridium (I) hexafluorophosphate [(C 6 H ⁇ ) 3 P[C 8 H 12 ][C 5 H 5
- transition metal complexes such as palladium acetylacetonate, tris(triphenylphosphine)r
- the present invention also provides two alternative routes to anhydroluteins from unsaponified extracts of marigold oleoresin that contains lutein fatty acid esters (e.g. lutein bispalmitate, lutein bismyristate, lutein 3-myristate 3'-palmitate, lutein 3-palmitate 3'-myristate), as shown in the scheme of Fig. 2.
- Lutein esters in marigold oleoresin are also accompanied by approx. 5-9% of zeaxanthin fatty acid esters (e.g. zeaxanthin bismyristate, zeaxanthin 3-myristate 3'-palmitate, zeaxanthin bispalmitate).
- anhydroluteins from unsaponified extracts of marigold oleoresin is accomplished by acid-catalyzed transesterification of lutein esters with an alcohol at an elevated temperature, preferably between about 45 to 50°C.
- an alcohol at an elevated temperature, preferably between about 45 to 50°C.
- the acylester at the 3 '-position in lutein esters preferentially undergoes transesterification while the acylester group at the 3 -position remains unchanged.
- the transesterification is also accompanied by etherification at the 3 '-position (see the scheme of Fig. 2).
- the resulting lutein 3-acylester 3 '-alkyl ether can then be converted to anhydroluteins at elevated temperature, preferably ranging from about 78 to 88°C.
- lutein 3-acyl ester 3'- alkyl ether can be subjected to saponification to hydrolyze the acyl ester at the 3-position and yield lutein 3 '-alkyl ether; the latter can then be converted to anhydroluteins according to the PCT US03/23422.
- Catalytic hydrogenation of the resulting anhydroluteins according to the processes of the present invention can yield a mixture of (3R)- ⁇ -cryptoxanthin and (3R,6'R)- ⁇ -cryptoxanthin.
- (3R,3'R)-Zeaxanthin esters that are present as minor constituents in the starting material are converted to unesterified (3R,3'R)-zeaxanthin but otherwise remain unchanged throughout the entire process.
- the present invention also improves the process that converts lutein to anhydroluteins by reducing the volume of solvents and increasing the purity and stability of the products.
- the present invention further demonstrates that lutein-containing products with considerable amounts of water content, hereinafter referred to as wet lutein, can be employed to convert this carotenoid to anhydroluteins in excellent yields.
- wet lutein includes any lutein- containing product that includes more water than dry lutein-powder. Specifically included in the term wet lutein is the product produced as described in United States Patent No. 5,648,564 at the point where water has been added to the saponified oleoresin and some of the liquid removed by centrifugation. Kemin Industries (Des Moines, Iowa) sells OroGLO® Liquid products that are also included in the term wet lutein. (3R)- ⁇ -Cryptoxanthin and (3R,6'R)- ⁇ -cryptoxanthin can be used as dietary supplements, nutritional ingredients, or as a food coloring additives. The commercial availability of these carotenoids allows scientists to investigate the potential chemopreventive efficacy of these compounds as neuroprotectors and in the promotion of bone health as well as in the prevention of cancer, cardiovascular disease, and macular degeneration.
- Fig. 1 is a scheme which depicts the conversion of (3R,3'R,6'R)-lutein to ⁇ - cryptoxanthin and ⁇ -cryptoxanthin; (3R,3'R)-zeaxanthin which is present in the starting material remains unreacted throughout the entire process and is recovered in the final product.
- Fig. 1 is a scheme which depicts the conversion of (3R,3'R,6'R)-lutein to ⁇ - cryptoxanthin and ⁇ -cryptoxanthin; (3R,3'R)-zeaxanthin which is present in the starting material remains unreacted throughout the entire process and is recovered in the final product.
- 3R,3'R)-zeaxanthin esters that are present as minor constituents in the starting material are converted to unesterified (3R,3'R)-zeaxanthin but otherwise remain unchanged throughout the entire process.
- the resulting product of this isomerization is a mixture of anhydroluteins in which anhydrolutein IH is the major product and the rest is anhydrolutein I and anhydrolutein II as well as minor quantities of unreacted zeaxanthin (Fig. 1).
- this mixture is subjected to ionic hydrogenation with a strong acid and a hydride ion donor at ambient temperature to yield (3R)- ⁇ -cryptoxanthin and (3R,6'R)- ⁇ - cryptoxanthin in excellent yields.
- the present invention relates to a catalytic hydrogenation process that converts a mixture of anhyroluteins which consists of approximate ratios of anhydrolutein I: anhydrolutein II: anhydrolutein III (1.4:1.0:10) to a mixture of ⁇ -cryptoxanthin and ⁇ - cryptoxanthin by heterogeneous and homogeneous catalytic hydrogenation in a variety of solvents under mild conditions at atmospheric or elevated pressure (Fig. 1).
- the heterogeneous catalyst may be selected from the transition elements of group VIII such as platinum (Pt) supported on alumina (5%), Pt supported on activated carbon (5% or 10%), palladium (Pd) supported on activated carbon (Pd/C, 5% or 10%), Pd supported on alumina (5% or 10%), Pd supported on calcium carbonate (Pd/CaCO 3 , 5%), Pd 3% on polyethyleneimine/SiO 2 (Royer Pd catalyst), or rhodium (Rh) supported on alumina (5%).
- group VIII such as platinum (Pt) supported on alumina (5%), Pt supported on activated carbon (5% or 10%), palladium (Pd) supported on activated carbon (Pd/C, 5% or 10%), Pd supported on alumina (5% or 10%), Pd supported on calcium carbonate (Pd/CaCO 3 , 5%), Pd 3% on polyethyleneimine/SiO 2 (Royer Pd catalyst), or rhodium (R
- the homogeneous catalyst may be transition metal complexes such as palladium acetylacetonate, tris(triphenylphosphine)rhodium (I) chloride [Rh(Ph 3 P) 3 Cl] (Wilkinson's catalyst), (tricyclohexylphosphine)(l,5-cyclooctadiene)pyridine Iridium (I) hexafluorophosphate [(C 6 H ⁇ 1 ) 3 P[C 8 H 12 ][C 5 H 5 N]Ir + PF6 " (Crabtree catalyst), and (1,5- cyclooctadiene)bis(methyldiphenylphosphine) iridium (I) hexafluorophosphate [C 8 H 12 ] [(MePh 2 P) 2 ]Ir + PF6-.
- transition metal complexes such as palladium acetylacetonate, tris(triphenylphosphine
- heterogeneous and homogeneous hydrogenation reactions are preferentially carried out under an atmospheric pressure of hydrogen.
- heterogeneous catalytic hydrogenation reactions conducted with Pt under hydrogen pressures of 40-60 psi produce similar results to those carried out at atmospheric pressure.
- the heterogeneous catalytic hydrogenation of anhydroluteins can be carried out with 1.4-5.0 mol% (0.5-1.8 weight%) of the catalyst to substrate to give moderate to excellent yields of (3R)- ⁇ -cryptoxanthin and (3R,6'R)- ⁇ -cryptoxanthin.
- the homogeneous catalytic hydrogenation reactions require 3-10 mol% of catalyst to substrate to produce a low to moderate yield of the desired products.
- a wide range of solvents in which anhydroluteins are soluble, can be employed with this catalytic hydrogenation; these include but are not limited to: ethyl acetate, acetone, tetrahydrofuran (THF), tert-butyl methyl ether (TBME), toluene, and chlorinated solvents (dichloromethane, chloroform, 1,2-dichloroethane).
- the range of temperature for the heterogeneous catalytic hydrogenation with transition elements of group VIII is between -15 to 100°C and preferably between about -15 to about 40°C.
- the reaction is preferably carried out at temperatures ranging from about 20 to 80°C and most preferably between about 45 to about 50°C.
- Homogeneous catalytic hydrogenations can be carried out over a wide range of temperatures, and are commonly carried out at ambient temperature with the exception of reactions carried out with palladium acetylacetonate that are preferably carried out at between about 45 to 50°C.
- the starting material comprising of a mixture of anhydrolutein I, II, and III, may be prepared from commercially available (3R,3'R,6'R)-lutein by modification of the process described in earlier filed PCT application US03/23422.
- the modification involves the use of an ether (including, but not limited to, THF, tert-butyl methyl ether, ethyl ether, diisopropyl ether) as a co-solvent to enhance the solubility of lutein and reduce the volume of alcohol.
- Suitable alcohols include, but are not limited to, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, isobutyl alcohol, tert-butyl alcohol, 1-pentanol (n-amyl alcohol), 2-pentanol, n- hexyl alcohol, n-octyl alcohol, ethylene glycol, and propylene glycol.
- the present invention demonstrates that the dehydration of lutein can also be carried out with wet lutein as opposed to dried lutein powder.
- This alternative process eliminates the use of a co-solvent and, at the same time, reduces the volume of the alcohol employed in the dehydration of lutein.
- Wet lutein contains substantial amounts of water with approximately 38% lutein content and is produced in the process described in United States Patent No.
- anhydroluteins which are the precursors to ⁇ -cryptoxanthin and ⁇ -cryptoxanthin, can be directly prepared from esterified lutein by acid-catalyzed transesterification (Fig. 2). Lutein esterified with fatty acids such as myristic and palmitic are abundant in certain natural products, particularly in the crude extracts of marigold flowers, and can serve as an economically viable raw material for the synthesis of anhydroluteins.
- 3R,3'R,6'R Three types of (3R,3'R,6'R)-lutein may be employed as starting materials in this invention, these are: 1) commercially available dried (3R,3'R,6'R)-lutein powder; 2) a purified product of lutein powder with greater than 97% total carotenoid content which is obtained by recrystallization of lutein powder; 3) wet lutein containing water with some not insignificant lutein content; and 4) marigold oleoresin containing a mixture of lutein fatty acid esters, examples of which include lutein bismyristate, lutein bispalmitate, lutein 3- myristate 3'palmitate, and lutein 3-palmitate 3'myristate.
- Marigold oleoresin is prepared from extracts of marigold flowers and typically contains approximately 3% (wt/wt) of lutein after saponification dependent, of course, on the lutein content of the marigold flowers.
- Saponified marigold oleoresin is also the precursor of a wet lutein product that is used to prepare lutein powder.
- Saponified marigold oleoresin contains (3R,3'R)-zeaxanthin which remains unreacted throughout all of the processes described in the present invention.
- saponified marigold oleoresin contains between approximately 5 and 9% of (3R,3'R)-zeaxanthin relative to (3R,3'R, 6'R)-lutein (91-95%).
- the yield of this reaction based on total carotenoid content of the dried product from various experiments ranges from 65% to 75%; the final product consists in excess of 80% anhydrolutein III and the remainder is anhydroluteins I and II as well as minor quantities of (3R,3'R)-zeaxanthin. As shown by HPLC, no significant amount of Z(cis)-isomers of anhydroluteins are present in the crystallized products.
- a suspension of 40 g of wet lutein (38% lutein content) in n-propanol (100 ml), water (50 ml), and aqueous HCl (10 ml, 6 N) is mechanically stirred at reflux temperature (88-90°C) under an atmosphere of nitrogen for nearly 16 h. After cooling to room temperature, the acid is neutralized and the red crystals are collected by filtration and washed with water and an alcohol.
- the dried product (13.7 g, total carotenoids) consists of anhydroluteins in a ratio of anhydrolutein I: anhydroluteins II: anhydrolutein III (1.9:1.0:10.9) as well as minor quantities of (3R,3'R)-zeaxanthin. Therefore the invention relates to a modified process of reacting dried lutein or wet powder with an alcohol in the presence of catalytic amount of an acid at above ambient temperature, preferably at 78-88°C, to obtain a mixture of anhydroluteins rich in anhydrolutein m. Alternatively, the invention relates to a modified process in which a small volume (1-
- the work-up and washing of the product comprises washing the crystalline product with a small volume of a hydrocarbon solvent (pentane, hexane, petroleum ether) to remove the unsaturated hydrocarbons that may be present as by-products as well as facilitating the removal of alcohol and drying of the final products.
- a hydrocarbon solvent penentane, hexane, petroleum ether
- lutein esters (esterified with myristic and palmitic acids) dissolved in a hydrocarbon solvent or an ether undergo transesterification in n-propanol in the presence of catalytic amount of a mineral acid under controlled conditions at 45-50°C to yield mainly lutein 3-myristate 3'- propyl ether and lutein 3-palmitate 3 '-propyl ether in about 21 h. This has been confirmed by monitoring by HPLC the formation of the products before and after saponification.
- HPLC Prior to saponification, HPLC clearly shows the absence of lutein, lutein 3 '-propyl ether, and/or anhydroluteins while saponification of the product yields exclusively lutein 3 '-propyl ether.
- the ease with which the ⁇ , ⁇ -unsaturated ester group at C-3' in lutein esters undergoes transesterification is most likely due to its allylic nature as opposed to the ester group at C-3 which is not allylic and remains unchanged.
- transesterification of lutein esters results in the formation of lutein 3-acylester which in the presence of catalytic amount of an acid and n- propanol undergoes etherification at C-3' to form lutein 3-acylester 3 '-propyl ether.
- the ester group at C-3 also undergoes acid-catalyzed transesterification to yield lutein 3 '-propyl ether.
- transesterification is also accompanied by the loss of n-propanol from lutein 3 '-propyl ether and yields a mixture of anhydroluteins I, II, and III.
- the present invention isolates lutein 3-acylester 3 '-propyl ether and subjects this product to saponification to prepare lutein 3 '-propyl ether; the latter is then converted to anhydroluteins according to the procedure described in PCT US03/23422.
- the present invention relates to a method of reacting lutein esters dissolved in a hydrocarbon or an ether with catalytic amount of an acid in the presence of an alcohol to obtain a mixture of anhydroluteins, comprising reacting lutein esters with an alcohol in the presence of catalytic amount of an acid at ambient or elevated temperatures below 60°C, preferably between 45-60°C, to obtain a mixture of lutein 3-acylester 3 '-alkyl ether, adding water and additional acid and raising the temperature to preferably between 78-88°C to convert the fore-mentioned mixture to anhydroluteins I, II, and III.
- the reaction comprises: a) dissolving commercially available lutein esters containing minor amounts of zeaxanthin esters from marigold oleoresin in an appropriate volume (about 2 ml/g of marigold oleoresin) of a hydrocarbon solvent (e.g. pentane, hexane, petroleum ether) or an ether (e.g. THF, diethyl ether, diisopropyl ether, tert-butyl methyl ether), adding an alcohol (1.2 ml/g of marigold oleoresin) and catalytic amount of an acid in alcohol [e.g.
- a hydrocarbon solvent e.g. pentane, hexane, petroleum ether
- an ether e.g. THF, diethyl ether, diisopropyl ether, tert-butyl methyl ether
- lutein esters are converted to a mixture of lutein 3- myristate 3 '-alkyl ether and lutein 3-palmitate 3 '-alkyl ether under controlled conditions and the isolated products are then subjected to alkaline hydrolysis to yield lutein 3 '-alkyl ether; this is further converted to anhydroluteins at temperatures between 78-90°C.
- the reactions comprise: a) dissolving commercially available lutein esters containing minor amounts of zeaxanthin esters from marigold oleoresin in an appropriate volume (about 2 ml/g of marigold oleoresin) of a hydrocarbon solvent (e.g.
- 3 '-alkyl ether c) cooling down the product to ambient temperature and hydrolyzing the mixture with an alcoholic solution of a mineral base (e.g. KOH/methanol, NaOH/methanol) for 2-3 hours at ambient temperature; d) washing the saponified products with water and evaporating most of the solvent to obtain a concentrated residue; e) crystallizing lutein 3 '-alkyl ether and minor quantities of zeaxanthin from the residue by adding a 1/1 solution (v/v) of an alcohol in water, preferably, methanol or ethanol in water and collecting the crystals by filtration; f) suspending the crystalline lutein 3 '-alkyl ether in an appropriate volume (about 3 ml) of an alcohol and water (about 3 ml), and adding a catalytic amount of an aqueous acid (e.g.
- a mineral base e.g. KOH/methanol, NaOH/methanol
- the invention relates to a process for hydrogenating a mixture of anhydroluteins to ⁇ - cryptoxanthin and ⁇ -cryptoxanthin in the presence of catalytic amount of transition elements of group VIII in a variety of organic solvents at temperatures ranging from -15°C to 40°C under atmospheric pressure of hydrogen (Fig. 1).
- the catalysts may be platinum (Pt) supported on alumina (5%), Pt supported on activated carbon (5% or 10%), palladium (Pd) supported on activated carbon (Pd/C, 5% or 10%), Pd supported on alumina (5% or 10%), Pd supported on calcium carbonate (Pd/CaCO 3 , 5%), Pd 3% supported on polyethyleneimine/Si ⁇ 2 (Royer Pd catalyst), or rhodium (Rh) supported on alumina (5%).
- the results of hydrogenation experiments with these catalysts are summarized in Tables 1, 2 and 3.
- Yield (%) of total carotenoids refers to the crude mixture of ⁇ -cryptoxanthin and ⁇ -cryptoxanthin that contains minor quantities of anhydroluteins I and II and (3R,3 'R)-zeaxanthin.
- the carotenoid concentration of this mixture is measured by HPLC as well as UV-visible spectrophotometry using an average extinction coefficient (El%) of 2511 in hexane.
- the mixture is stirred at 40°C and 40 PSI of hydrogen. After 14 hours, the reaction mixture is allowed to cool down to ambient temperature, and filtered through celite. The filtrate is concentrated under reduced pressure below 40°C and the residue is crystallized from a solution of ethyl acetate/ethanol/water. The dark orange crystals are collected by filtration. The wet product was obtained as an orange solid (800 g, total carotenoid purity 20.4%, total carotenoid yield 85.5%, ⁇ -cryptoxanthin purity 9.89%, ⁇ - cryptoxanthin yield from anhydrolutein III 62.6%).
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3'R)- zeaxanthin. The results of this experiment is summarized in the first last data row of Table 2.
- Pd supported on carbon or alumina Pd supported on calcium carbonate poisoned with lead (Lindlar's catalyst) and Pd supported on polyethyleneimine/silica gel can also be employed to hydrogenate a mixture of anhydroluteins to ⁇ -cryptoxanthin and ⁇ -cryptoxanthin in low to moderate yields.
- the other Pd supported catalysts are quite reactive and effect this transformation at -15°C.
- the present invention relates to a method of hydrogenating a mixture of anhydroluteins I, II, III rich in anhydrolutein III to ⁇ -cryptoxanthin and ⁇ -cryptoxanthin in the presence of catalytic amount of transition elements of group VIII, preferably Pt supported on alumina, in a variety of organic solvents at temperatures ranging from -15°C to 100°C, and preferably between about -15°C and about 50°C, under atmospheric or elevated pressure of hydrogen.
- the reaction comprises: a) dissolving anhydroluteins with purities ranging from 45-75% in an appropriate volume of an organic solvent ( «35 ml/g of anhydroluteins), preferably ethyl acetate, adding catalytic amount of 5% Pt supported on alumina (1.4-2.2 mol% of catalyst to substrate) to obtain a mixture; b) displacing the air with an inert gas, preferably argon, and then displacing the inert gas with hydrogen; c) stirring the mixture under an atmospheric pressure of hydrogen between -15°C to 50°C, preferably at about 40°C, for about 10-26 hours to obtain a mixture of ⁇ -cryptoxanthin and ⁇ -cryptoxanthin; d) removing the catalyst by filtration through celite and concentrating the filtrate under reduced pressure below 40°C to obtain a concentrated residue containing ⁇ - cryptoxanthin and ⁇ -cryptoxanthin; e) crystallizing ⁇ -crypt
- the invention relates to a process for hydrogenating a mixture of anhydroluteins to ⁇ - cryptoxanthin and ⁇ -cryptoxanthin in low to moderate yields in the presence of catalytic amount of several transition metal complexes.
- the homogeneous catalyst may be transition metal complexes such as palladium acetylacetonate, tris(triphenylphosphine)rhodium (I) chloride [Rh(Ph P) 3 Cl] (Wilkinson's catalyst), (tricyclohexylphosphine)(l,5- cyclooctadiene)pyridine Iridium (I) hexafluorophosphate [(C 6 H ⁇ ) 3 P[C 8 H ⁇ 2 ][C 5 H 5 N]Ir + PF6 " (Crabtree catalyst), and (l,5-cyclooctadiene)bis(methyldiphenylphosphine) Iridium (I) hexafluorophosphate [C 8 H ⁇ 2 ][(MePh 2 P) 2 ]Ir + PF6 " .
- transition metal complexes such as palladium acetylacetonate, tris(triphenylphosphine
- the reactions are all preferably carried out under atmospheric pressure of hydrogen and at ambient temperature.
- the exception is the hydrogenation reaction involving palladium acetylacetonate that is preferably carried out at 45-50°C.
- the results of hydrogenation experiments with these homogeneous catalysts are summarized in Table 4.
- Wilkinson's catalyst (Ph 3 P) 3 RhCl] converts anhydroluteins to ⁇ -cryptoxanthin and ⁇ -cryptoxanthin in almost quantitative yields.
- the only regioselective hydrogenation of a highly conjugated polyene system that has been reported in the literature with Wilkinson's catalyst is the hydrogenation of a retinoid derivative, namely, 3,4-didehydro-9-cis-retinoic acid [Bennani, Y.I., Boehm, M.F. J. Org.
- the present invention further relates to a method of hydrogenating a mixture of anhydroluteins I, II, III rich in anhydrolutein III to ⁇ -cryptoxanthin and ⁇ -cryptoxanthin in the presence of catalytic amount of transition metal complexes, preferably Wilkinson's catalyst [(Ph 3 P) 3 RhCl] in a variety of organic solvents at ambient temperature under atmospheric pressure of hydrogen.
- catalytic amount of transition metal complexes preferably Wilkinson's catalyst [(Ph 3 P) 3 RhCl] in a variety of organic solvents at ambient temperature under atmospheric pressure of hydrogen.
- the reaction comprises: a) dissolving anhydroluteins with purities ranging from 45-75% in an appropriate volume of an organic solvent ( «50 ml/g of anhydroluteins), preferably ethyl acetate, adding stoichiometric amount of (Ph 3 P) 3 RhCl (2.2 mol equivalent of catalyst to substrate) to obtain a mixture; b) displacing the air with an inert gas, preferably argon, and then displacing the inert gas with hydrogen; c) stirring the mixture under an atmospheric pressure of hydrogen at ambient temperature for about 2 hours to obtain a mixture of ⁇ -cryptoxanthin and ⁇ -cryptoxanthin; d) removing the catalyst by filtration through celite and concentrating the filtrate under reduced pressure below 40°C to obtain a concentrated residue containing ⁇ - cryptoxanthin and ⁇ -cryptoxanthin; e) crystallizing ⁇ -cryptoxanthin and ⁇ -cryptoxanthin
- Example A Conversion of (3R,3'R,6'R)-Lutein (85% pure to Anhydroluteins L IL and III with Hydrochloric Acid in n-Propanol and Tetrahydrofuran (THF-) (3R,3'R,6'R)-Lutein (6.0 g of 85% lutein content » 5.10 g, 8.98 mmol) is placed in a
- Example B Conversion of Wet (3R.3'R,6'R)-Lutein (38% pure) to Anhydroluteins L IL and SI with Hydrochloric Acid in n-Propanol
- a suspension of lutein wet cake (40.0 g, 38% « 15.2 g, 26.8 mmol) in 1-propanol (100 ml) and water (50 ml) is mechanically stirred at 400 rpm in a 1000 ml four-neck flask, equipped with a condenser, a mechanical stirrer, a thermometer, and a nitrogen inlet.
- Example C Direct Conversion of Lutein Esters to Anhydroluteins L IL and III by Acid- Catalyzed Transesterification Marigold oleoresin (5 g) containing lutein esters (from Kemin Foods, Des Moines, Iowa) is dissolved in hexane (10 ml) and is treated with n-propanol (6 ml) and 0.5 ml of 10% hydrochloric acid in propanol (v/v). The mixture is heated at 60°C and the course of the reaction is followed by HPLC (Khachik & Beecher, J. Chromatogr. 449: 119-133, 1988).
- carotenol fatty acid esters are converted to a mixture of lutein 3-myristate 3 '-propyl ether, lutein 3-palmitate 3 '-propyl ether, as well as myristic and palmitic esters of anhydroluteins I, II, and III.
- Water (6 ml) and 0.5 ml of aqueous HCl (18-19%, v/v) is added and the temperature of the reaction mixture is gradually raised to distill off the hexane. After removal of hexane, the temperature is raised to 90°C and the mixture is refluxed in n-propanol for 22 h.
- the reaction mixture is allowed to cool down to ambient temperature and the acid is neutralized with an aqueous solution of NaOH (10%).
- the product is extracted with tert-butyl methyl ether (10 ml) and the aqueous layer is removed.
- the organic layer is treated with 10 ml of methanolic KOH (10%) and stirred at ambient temperature for 2 h.
- the saponified product is washed with water (3 X 10 ml), dried over sodium sulfate, and most of the solvents are evaporated.
- Example D Conversion of Lutein Esters to Anhydroluteins L IL and III via Lutein 3 '-Alkyl Ether Marigold oleoresin (5 g) containing lutein esters (from Kemin Foods) is dissolved in hexane (10 ml) and is treated with n-propanol (6 ml) and 0.5 ml of 10% hydrochloric acid in propanol (v/v). The mixture is heated at 45-50°C and the course of the reaction is followed by HPLC. After 21 h, the reaction mixture is allowed to cool down to ambient temperature; 10 ml of methanolic KOH (10%) is added and stirring is continued at ambient temperature for 2 h.
- the saponified product is washed with water (3 X 10 ml), dried over sodium sulfate, and most of the solvents are evaporated.
- the residue is crystallized from a 1/1 solution of ethanol/water (v/v) to give 263 mg of orange crystals that is shown by HPLC to be 60% pure lutein 3 '-propyl ether (157.8 mg) as well as minor quantities of (3R,3'R)-zeaxanthin.
- the crystalline product is suspended in n-propanol (3 ml) and water (3 ml) and is treated with 0.2 ml of 18-19% hydrochloric acid in water (v/v).
- Example A Catalytic Hydrogenation of Anhydroluteins I, IL III (75% total carotenoids) with Platinum (5%) Supported on Alumina in Ethyl Acetate at -5°C
- To a mixture of 75% total carotenoids (0.3 g « 0.225 g) and platinum (5%) supported on alumina (80 mg » 4.0 mg Pt) in a 60 ml glass reaction tube is added 20 ml of ethyl acetate and the tube is cooled down to -5°C to 0°C in an ice/salt bath. The tube is evacuated and filled with hydrogen several times, and then sealed. The mixture is stirred at -5 to 0°C and the course of the reaction is followed by HPLC.
- HPLC shows nearly the complete conversion of anhydroluteins to the desired products.
- Approximately 30 ml of hydrogen (1.34 mmol) is required to complete the reaction.
- the product is allowed to warm up to ambient temperature and filtered through celite to remove the catalyst.
- the filtrate is concentrated under reduced pressure below 40°C and the residue is crystallized from 10 ml of a 1/1 solution of ethanol/water.
- the product (0.24 g, total carotenoids yield 70%) consists of a mixture of ⁇ -cryptoxanthin and ⁇ -cryptoxanthin in the ratio of 3:1.
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3'R)-zeaxanthin.
- Example B Catalytic Hydrogenation of Anhydroluteins L IL III (75% total carotenoids with Platinum (5%) Supported on Alumina in Ethyl Acetate at -15°C
- To a mixture of 75% total carotenoids(0.3 g « 0.225 g) and platinum (5%) supported on alumina (80 mg « 4.0 mg Pt) in a 60 ml glass reaction tube is added 20 ml of ethyl acetate and the tube is cooled down to -15°C in a low temperature freezer. The tube is evacuated and filled with hydrogen several times, and then sealed. The mixture is stirred at -15°C and the course of the reaction is followed by HPLC.
- HPLC shows nearly the complete conversion of anhydroluteins to the desired products.
- the product is allowed to warm up to ambient temperature and is filtered through celite to remove the catalyst.
- the filtrate is concentrated under reduced pressure below 40°C and the residue is crystallized from 10 ml of a 1/1 solution of ethanol/water. The dark orange crystals are collected by filtration, washed with 5 ml of cold ethanol, and dried under high vacuum below 40°C.
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3 'R)-zeaxanthin.
- Example C Catalytic Hydrogenation of Anhydroluteins L IL III (45% total carotenoids) with Platinum (5%) Supported on Alumina in Ethyl Acetate at 40°C
- a three-neck round bottom flask is equipped with a mechanical stirrer, a thermometer, and a gas inlet. The flask is charged with a mixture of anhydroluteins (20.0 g, 45% total carotenoids, 28% anhydrolutein III), platinum (5%) supported on alumina (1.0 g,), and ethyl acetate (700 ml). The air is displaced with argon and the mixture was heated to 40°C with mechanical stirring at 500 rpm.
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3'R)-zeaxanthin.
- Example D Catalytic Hydrogenation of Anhydroluteins I, IL HI (49% total carotenoids) with Platinum (5%) Supported on Alumina in Ethyl Acetate at 40°C
- a three-neck round bottom flask is equipped with a mechanical stirrer, a thermometer, and a gas inlet.
- the flask is charged with a mixture of anhydroluteins (20.0 g, 49% total carotenoids, 27% anhydrolutein III), platinum (5%) supported on alumina (1.0 g), and ethyl acetate (700 ml).
- the air is displaced with argon and the mixture is heated to 40°C with mechanical stirring at 500 rpm.
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3 'R)-zeaxanthin.
- Example E Catalytic Hydrogenation of Anhydroluteins I, IL III (49% total carotenoids) with Platinum (5%) Supported on Alumina in Ethyl Acetate at 40°C
- a three-neck round bottom flask is equipped with a mechanical stirrer, a thermometer, and a gas inlet.
- the flask is charged with a mixture of anhydroluteins (20.0 g, 49% total carotenoids, 27% anhydrolutein III), platinum (5%) supported on alumina (1.5 g), and ethyl acetate (700 ml).
- the air is displaced with argon and the mixture is heated to 40°C with mechanical stirring at 500 rpm.
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3 'R)-zeaxanthin.
- Example F Catalytic Hydrogenation of Anhydroluteins I, II.
- Ill (75% total carotenoids) with Palladium (5%) Supported on Carbon in Ethyl Acetate at -15°C
- To a mixture of 75% total carotenoids (0.3 g « 0.225 g) and palladium (5%) supported on carbon (26 mg « 1.3 mg Pd) in a 60 ml glass reaction tube is added 20 ml of ethyl acetate and the mixture is cooled down to -15°C in a low temperature freezer. The tube is evacuated and filled with hydrogen several times and then sealed. The mixture is stirred at-15°C and the course of the reaction is followed by HPLC.
- HPLC shows nearly the complete conversion of anhydroluteins to the desired products.
- the product is allowed to warm up to ambient temperature and is filtered through celite to remove the catalyst.
- the filtrate is concentrated under reduced pressure below 40°C and the residue is crystallized from 10 ml of a 1/1 solution of ethanol/water.
- the dark orange crystals are collected by filtration, washed with 5 ml of cold ethanol, and dried under high vacuum below 40°C.
- HPLC also shows the presence of minor quantities of unreacted anhydroluteins I and II as well as (3R,3 'R)-zeaxanthin.
- Example A Catalytic Hydrogenation of Anhydroluteins I, IL III (75% total carotenoids) with Palladium Acetylacetonate in Tetrahydrofuran (THF) at 45-50°C
- THF Tetrahydrofuran
- the concentrated residue is crystallized from 10 ml of a 1/1 solution of ethanol/water.
- the dark orange crystals are collected by filtration, washed with 5 ml of cold ethanol, and dried under high vacuum below 40°C.
- HPLC also shows the presence of minor quantities of (3R,3 'R)-zeaxanthin.
- Example B Catalytic Hydrogenation of Anhydroluteins L IL III (75% total carotenoids) with Chlorotris(triphenylphosphine)Rhodium(I) in Ethyl Acetate at Ambient Temperature
- 75% total carotenoids 0.3 g « 0.225 g
- (Ph 3 P) 3 RhCl 835 mg
- a 40 ml glass reaction tube is added 15 ml of ethyl acetate and the mixture is cooled down to 0°C in an ice bath.
- the tube is evacuated and the solution is degassed under nitrogen.
- the tube is then evacuated and filled with hydrogen several times and sealed.
- HPLC also shows the presence of minor quantities of (3R,3 'R)- zeaxanthin.
- Example C Catalytic Hydrogenation of Anhydroluteins L IL III (63% total carotenoids, 45% anhydrolutein III) with Chlorotris(triphenylphosphine)Rhodium(I) in Ethyl Acetate at Ambient Temperature
- a suspension of Wilkinson's catalyst (100 mg, 0.11 mmol) in 2 ml of ethyl acetate ispurged by hydrogen and then magnetically stirred under hydrogen at room temperature for 2 hours.
- To the reaction mixture is added 50 mg of crude anhydroluteins (anhydrolutein III, 45%, 0.041 mmol). The mixture is stirred under hydrogen administered through a hydrogen balloon. After 2 hours, HPLC indicated complete consumption of anhydroluteins.
- the mixture is microfiltered and the filter is washed with 2 ml of ethyl acetate.
- the solvent is evaporated under nitrogen and the residue is dried under high vacuum for 2 h.
- the yield of ⁇ -cryptoxanthin based on anhydrolutein III is 96%.
- Example D Catalytic Hydrogenation of Anhydroluteins L IL III (75% total carotenoids) with [Ir(cod)Py(PcyV)] PFA " (Crabtree Catalyst) in Dichloromethane at Ambient Temperature
- To a mixture of anhydroluteins (75% total carotenoids, 0.3 g * 0.225 g) and [Ir(cod)Py(Pcy 3 )] PF 6 " (10 mg) in a 40 ml glass reaction tube is added 10 ml of dichloromethane and the mixture is cooled down to 0°C in an ice bath. The tube is evacuated and the solution is degassed under nitrogen.
- the tube is then evacuated and filled with hydrogen several times and sealed.
- the mixture is stirred at ambient temperature and the course of the reaction is followed by HPLC.
- HPLC shows that no additional amounts of ⁇ -cryptoxanthin and ⁇ -cryptoxanthin can be formed while considerable amounts of anhydroluteins remain unreacted.
- the product is filtered through celite and most of the solvent is evaporated under reduced pressure.
- the concentrated residue is crystallized from 10 ml of a 1/1 solution of ethanol/water. The dark orange crystals are collected by filtration and dried under high vacuum below 40°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51577103P | 2003-10-30 | 2003-10-30 | |
| PCT/US2004/035798 WO2005044769A1 (en) | 2003-10-30 | 2004-10-28 | Process for the preparation of alpha- and beta-cryptoxanthin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1678111A1 true EP1678111A1 (en) | 2006-07-12 |
| EP1678111A4 EP1678111A4 (en) | 2007-08-22 |
Family
ID=34572854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04796640A Withdrawn EP1678111A4 (en) | 2003-10-30 | 2004-10-28 | Process for the preparation of alpha- and beta-cryptoxanthin |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1678111A4 (en) |
| JP (1) | JP4468376B2 (en) |
| AU (1) | AU2004287843A1 (en) |
| CA (1) | CA2544384C (en) |
| WO (1) | WO2005044769A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2072536A1 (en) * | 2007-12-17 | 2009-06-24 | Lanxess Inc. | Hydrogenation of diene-based polymers |
| CN101828693B (en) * | 2009-03-09 | 2013-01-02 | 浙江医药股份有限公司新昌制药厂 | Preparation method and application of low-viscosity high-fluidity carotenoid oil suspension |
| JP2013536216A (en) * | 2010-08-24 | 2013-09-19 | ディーエスエム アイピー アセッツ ビー.ブイ. | Method for producing 3,7-dimethyl-1-octen-3-ol |
| CN113461582A (en) * | 2021-06-29 | 2021-10-01 | 青岛佳一生物科技股份有限公司 | Preparation method of cryptoxanthin |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10128454A1 (en) * | 2001-06-12 | 2002-12-19 | Zimmer Ag | Filament lubricating unit, at a cool blowing shaft, has a structured contour with good air flow characteristics to prevent turbulence at the filaments during lubrication |
| EP1480932B1 (en) * | 2002-02-06 | 2012-10-17 | University of Maryland, College Park | Method for production of beta-cryptoxanthin and alpha-cryptoxanthin from commercially available lutein |
-
2004
- 2004-10-28 AU AU2004287843A patent/AU2004287843A1/en active Pending
- 2004-10-28 CA CA2544384A patent/CA2544384C/en not_active Expired - Fee Related
- 2004-10-28 JP JP2006538242A patent/JP4468376B2/en not_active Expired - Lifetime
- 2004-10-28 WO PCT/US2004/035798 patent/WO2005044769A1/en not_active Ceased
- 2004-10-28 EP EP04796640A patent/EP1678111A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP4468376B2 (en) | 2010-05-26 |
| AU2004287843A1 (en) | 2005-05-19 |
| WO2005044769A1 (en) | 2005-05-19 |
| CA2544384C (en) | 2014-01-14 |
| CA2544384A1 (en) | 2005-05-19 |
| JP2007509957A (en) | 2007-04-19 |
| EP1678111A4 (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8097762B2 (en) | Process for the preparation of β- and α-cryptoxanthin | |
| TWI526417B (en) | An effective method for preparing lycopene oil-containing resin and lycopene crystal for human consumption | |
| US7271298B2 (en) | Process for isolation and purification of xanthophyll crystals from plant oleoresin | |
| JP3828252B2 (en) | Xanthophyll conversion method | |
| CA2544902C (en) | A process for isolating, purifying and formulating a stable, commercial grade lutein paste from oleoresin | |
| JP5794605B2 (en) | Methods for isolating carotenoids from plant sources | |
| JP4266924B2 (en) | Novel trans-lutein rich xanthophyll ester concentrate and process for its preparation | |
| EP2522655B1 (en) | Preparing method for xanthophyll crystals with higher content of zeaxanthin from plant oleoresin | |
| WO2010138210A1 (en) | Methods of saponifying xanthophyll esters and isolating xanthophylls | |
| CA2544384C (en) | Process for the preparation of alpha- and beta-cryptoxanthin | |
| Tan et al. | Hydrocarbon carotenoid profiles of palm oil processed fractions | |
| WO2008023283A2 (en) | Stabilized esters of lutein | |
| US9725411B2 (en) | Process for a direct one-pot transformation of lutein to β-cryptoxanthin via its acetate ester | |
| KR102816440B1 (en) | Unsaturated fatty acid esters of lutein, composition comprising the same and producing method thereof | |
| JPH11322708A (en) | Method for producing xanthophyll crystals | |
| Bogert | Recent Isoprene Chemistry. | |
| US20080015374A1 (en) | Method for the synthesis and isolation of phytosterol esters | |
| Paul | Functional Foods and Nutraceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060510 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20070723 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 403/24 20060101ALI20070717BHEP Ipc: C07C 35/21 20060101AFI20050523BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20101119 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LIU, YUFA Inventor name: KHACHIK, FREDERIK Inventor name: SCHOWALTER, HOLLY |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20140423 |